TDAC
NASDAQTranslational Development Acquisition Corp.
IPO2025
Price$10.72-0.04 (-0.37%)
05:00 PM06:30 PM
News · 26 weeks13+400%
2025-12-072026-05-31
Mix1390d
- SEC Filings9(69%)
- Other2(15%)
- Offering1(8%)
- Insider1(8%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Translational Development Acquisition Corp.SCHEDULE 13G - Translational Development Acquisition Corp. (0001926599) (Subject)
- INSIDERSEC Form 4 filed by Chairman and CEO Hoffman Michael B4 - Translational Development Acquisition Corp. (0001926599) (Issuer)
- SECSEC Form DEFA14A filed by Translational Development Acquisition Corp.DEFA14A - Translational Development Acquisition Corp. (0001926599) (Filer)
- SECSEC Form DEF 14A filed by Translational Development Acquisition Corp.DEF 14A - Translational Development Acquisition Corp. (0001926599) (Filer)
- SECSEC Form 425 filed by Translational Development Acquisition Corp.425 - Translational Development Acquisition Corp. (0001926599) (Subject)
- SECTranslational Development Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Translational Development Acquisition Corp. (0001926599) (Filer)
- PRProLogium, a Next Generation Solid-State Battery Developer with 10+ Years of Proven Commercialization, to List on the Nasdaq through a Merger with Translational Development Acquisition Corp.ProLogium reached commercial-scale manufacturing for solid-state batteries in 2013, later delivered the world's first solid-state battery demo car with ENOVATE Motor in 2019. ProLogium has shipped a total of over 2.4 million battery cells to customers since 2013, of which more than 800,000 are its 3rd-generation batteries from the Gigafactory in Taiwan. With a portfolio of 1,100+ patents, ProLogium has introduced its 4th-generation superfluidized inorganic solid-state battery solution with zero thermal runaway, high energy density, low temperature performance, fast charging, competitive cost, and commercial readiness. Pre-money valuation of ProLogium is expected to be approximately $3.8 bill
- SECSEC Form 10-Q filed by Translational Development Acquisition Corp.10-Q - Translational Development Acquisition Corp. (0001926599) (Filer)
- SECSEC Form SCHEDULE 13G filed by Translational Development Acquisition Corp.SCHEDULE 13G - Translational Development Acquisition Corp. (0001926599) (Subject)
- SECAmendment: SEC Form 10-K/A filed by Translational Development Acquisition Corp.10-K/A - Translational Development Acquisition Corp. (0001926599) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Translational Development Acquisition Corp.10-K/A - Translational Development Acquisition Corp. (0001926599) (Filer)
- SECSEC Form PRE 14A filed by Translational Development Acquisition Corp.PRE 14A - Translational Development Acquisition Corp. (0001926599) (Filer)
- SECSEC Form 10-K filed by Translational Development Acquisition Corp.10-K - Translational Development Acquisition Corp. (0001926599) (Filer)
- SECSEC Form 10-Q filed by Translational Development Acquisition Corp.10-Q - Translational Development Acquisition Corp. (0001926599) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Translational Development Acquisition Corp.SCHEDULE 13G/A - Translational Development Acquisition Corp. (0001926599) (Subject)
- SECTranslational Development Acquisition Corp. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits8-K - Translational Development Acquisition Corp. (0001926599) (Filer)
- SECSEC Form 10-Q filed by Translational Development Acquisition Corp.10-Q - Translational Development Acquisition Corp. (0001926599) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Translational Development Acquisition Corp.SCHEDULE 13G/A - Translational Development Acquisition Corp. (0001926599) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Translational Development Acquisition Corp.SCHEDULE 13G/A - Translational Development Acquisition Corp. (0001926599) (Subject)
- SECSEC Form 10-Q filed by Translational Development Acquisition Corp.10-Q - Translational Development Acquisition Corp. (0001926599) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Translational Development Acquisition Corp.SCHEDULE 13G/A - Translational Development Acquisition Corp. (0001926599) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Translational Development Acquisition Corp.SCHEDULE 13G/A - Translational Development Acquisition Corp. (0001926599) (Subject)
- SECSEC Form SCHEDULE 13G filed by Translational Development Acquisition Corp.SCHEDULE 13G - Translational Development Acquisition Corp. (0001926599) (Subject)
- SECSEC Form SCHEDULE 13G filed by Translational Development Acquisition Corp.SCHEDULE 13G - Translational Development Acquisition Corp. (0001926599) (Subject)
- SECSEC Form 10-K filed by Translational Development Acquisition Corp.10-K - Translational Development Acquisition Corp. (0001926599) (Filer)
TDAC FAQ
5 questionsWhat does Translational Development Acquisition Corp. do?
Trident Acquisitions Corp. does not have significant operations. It intends to enter into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more target businesses primarily in the oil and gas or other natural resource sector. Trident Acquisitions Corp. was incorporated in 2016 and is headquartered in New York, New York.Where does TDAC stock trade?
Translational Development Acquisition Corp. (TDAC) is listed on NASDAQ.When did Translational Development Acquisition Corp. go public?
Translational Development Acquisition Corp. (TDAC) completed its IPO in 2025.What are analysts saying about TDAC?
Translational Development Acquisition Corp. has had 1 recent analyst action on file. The most recent action was from Northland Capital Markets: Outperform with a $1600.00 price target on 2021-09-21. Recent price targets cluster around $1600.00.How can I track TDAC on Quantisnow?
Quantisnow aggregates Translational Development Acquisition Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TDAC to receive live email and push alerts on every new disclosure.